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Subjects and Methods
This HIPAA-compliant study was approved by our institutional review board. The need for signed informed consent was waived.
Benchmark C-RADS Values From a Clinical Screening Program

Patient Population
From January 2005 through December 2011, we enrolled 7288 consecutive individuals referred from general medical practice for first-time CTC examination for the purpose of colorectal cancer screening. To obtain a typical screening population without a significantly increased risk for colorectal cancer, we excluded patients with a history of colorectal cancer, inflammatory bowel disease, polyposis syndromes, and colorectal surgery, as well as patients referred from incomplete optical colonoscopy or with suspicion of symptomatic colorectal cancer. A total of 6769 asymptomatic patients met inclusion criteria and composed the screening CTC cohort.
CT Colonography Technique
The CTC technique used in our screening program has been described in detail elsewhere [5] [6] [7] [8] . Briefly, patients undergo a bowel preparation protocol beginning 1 day before CTC consisting of complete colonic catharsis and tagging of residual material. The cathartic cleansing agent was sodium phosphate before 2008 and magnesium citrate thereafter; polyethylene glycol was substituted as needed in a minority of patients. Contrast material tagging of residual fluid and fecal material was achieved with 2.1% weight/volume barium and diatrizoate meglumine (Gastrografin, Bracco Diagnostics). During the CTC examination, colonic insufflation was achieved and maintained throughout image acquisition using automated continuous carbon dioxide delivered through a rectal catheter [9] . Patients were routinely scanned in both supine and prone positions, with decubitus positioning as needed [10] . Images were acquired with 8-to 64-MDCT scanners using 1.25-mm collimation, 1-mm reconstruction interval, 120 kVp, and either a fixed tube currenttime product (50-75 mAs) or tube-current modulation (range, 30-300 mA).
C-RADS
All screening CTC examinations were interpreted by a board-certified radiologist within our abdominal imaging section. All examinations were prospectively classified using C-RADS for both colorectal and extracolonic findings. The specific criteria for the various colorectal ("C") and extracolonic ("E") categories are listed in Table 1 . If there were multiple lesions (either colorectal or extracolonic), the examination was scored by the most advanced finding. In our practice, slight modifications from the original C-RADS document were made. There were no CTC examinations in our study awaiting prior comparison; thus, in our experience, C0 represents a true nondiagnostic examination. In a similar fashion, all examinations for which polyps 6 mm or larger could not be excluded were considered technically inadequate and were coded as C0; thus, all examinations coded as C2 were positive for nondiminutive polyps.
Individual polyps were identified using a combination of 3D reconstructions and 2D cross-sectional images; 3D renderings were used primarily for polyp detection (supplemented by 2D detection), and 2D images were used for confirmation in all cases [6, 11] . The maximum linear diameter (excluding the stalk, if pedunculated) of each polyp was measured in both 3D and 2D projections using electronic calipers [12] . The morphologic features (sessile, pedunculated, flat, mass, or submucosal or extrinsic) and segmental location (rectum, sigmoid, descending, transverse, ascending, or cecum) of each polyp were determined and recorded. Of note, the submucosal or extrinsic category is not explicitly described in the original C-RADS publication, but we have found this useful to describe some lesions. Furthermore, we categorize likely diverticular strictures with a masslike appearance as a benign C4 subcategory, because no C-RADS classification yet exists. For each polyp, a diagnostic confidence score of 1 (least confident) to 3 (most confident) was also recorded, as described in the text of the C-RADS publication [4] and elsewhere [13, 14] . For evaluation of extracolonic findings, 5 × 3-mm axial reconstructions of the supine series were primarily used, supplemented by the prone images as needed. The results of colonoscopy and polypectomy, as well as the final histologic result at pathologic analysis, were recorded for all patients undergoing polypectomy.
Criteria for colorectal classification by C-RADS are summarized in Table 1 . Positive cases were defined as patients with a C-RADS score of C2 through C4. In accordance with C-RADS, patients with a score of C3 or C4 were referred for colonoscopy with polypectomy, whereas patients with a score of C2 were given the option of either colonoscopy with polypectomy or CTC polyp surveillance. Patients with a score of C1 were considered to have a negative examination and were recommended to un- 
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dergo routine screening in 5 years. In our program, C0 was used exclusively to denote nondiagnostic examinations. The C-RADS criteria for classification of extracolonic findings are summarized in Table 1 .
It is important to note that, although categories E3 and E4 denote potentially significant extracolonic findings, further workup may or may not be indicated for a given patient and is dependent on a number of factors, including clinical scenario, previous diagnosis, and prior workup history [15] .
Experience of Radiologists
CTC examinations were interpreted by one of 11 board-certified radiologists during the study interval (mean, 615 examinations; range, 37-2122 examinations). All radiologists were board certified with an average of 9 years in practice by the conclusion of the study (range, 2-31 years). Nine of the 11 radiologists had completed a fellowship in abdominal radiology, and six of those had dedicated instruction in CTC. Six of the 11 radiologists work solely in the subspecialty area of abdominal imaging, whereas five have a more general radiology practice.
Statistical Analysis
The Fisher exact test was used to test for differences in categoric variables. The Student t test and analysis of variance were used, where appropriate, to test for differences in continuous variables. Two-tailed p < 0.05 was used as the criterion for statistical significance.
Results
The mean (± SD) age of the population (n = 6769) was 56.7 ± 6.1 years, with a male-to-female ratio of 3110 (45.9%) to 3659 (54.1%). The overall positive rate at CTC in this first-time screening cohort was 14.3% (969/6769), with a negative rate of 85.0% (5751/6769) and a nondiagnostic rate of 0.7% (49/6769). The overall distribution of C-RADS scores was 0.7% C0 (49/6769), 85.0% C1 (5751/6769), 8.6% C2 (579/6769), 5.2% C3 (351/6769), and 0.6% C4 (39/6769) ( Table 2) . This led to an overall colonoscopy referral rate of 8.7% (587/6769), reflecting the fact that many patients in the C2 category opt for CTC surveillance. Of the 579 patients with C2 findings, 66.0% (382/579) initially chose CTC surveillance and the remain- A total of 95.8% (551/575) of patients initially referred for polypectomy ultimately underwent polypectomy and 4.2% (24/575) deferred. Of patients who opted for CTC polyp surveillance, 97.0% (382/394) had a C-RADS score of C2; as mentioned already, there were 10 patients with scores of C3 and two patients with scores of C4 who refused polypectomy and thus were followed with CTC polyp surveillance. Of C2 patients who initially chose CTC polyp surveillance, 24.1% (92/382) ultimately underwent polypectomy, typically after discussing results with their primary care provider.
Overall, the men in this cohort were slightly older than the women (mean age, 56.9 ± 6.3 vs 56.5 ± 6.0 years; p = 0.0076). The positive rate (C2-C4) among men was 17.5% (545/3110) and was significantly higher than the 11.6% (424/3659) seen for women (p < 0.0001). The rate of nondiagnostic examinations (C0) was similar between men (0.7% [22/3110] ) and women (0.7% [27/3659] ; p = 0.8868). Positive rates increase dramatically as patients age (Table 2), with rates of 13.4% (811/6043) for patients 50-64 years old and 21.8% (158/726) for patients 65-79 years old (p < 0.0001).
Overall, 0.7% (49/6769) patients had a technically inadequate study (C-RADS classification C0). Of these studies, the reason for this was poor luminal distention in 49% (24/49), poor bowel preparation in 31% (15/49), and both poor distention and preparation in 16% (8/49) of cases. In addition, two patients could not be evaluated because of technical issues with the 3D reconstruction software. Clinical management of this heterogeneous group was handled on a case-by-case basis in terms of follow-up strategies.
The distribution of extracolonic classification scores was 0.0% E0 (0/6769), 35.7% E1 (2416/6769), 50.9% E2 (3445/6769), 11.3% E3 (764/6769), and 2.1% E4 (144/6769) (Table 2). Overall, 13.4% (908/6769) of patients had indeterminate or potentially significant extracolonic findings (E3 or E4). Rates of E3 or E4 extracolonic findings increased with age from 12.8% (774/6043) for patients 50-64 years old to 18.5% (134/726) for patients 65-79 years old (p < 0.0001). Women were also significantly more likely than men to have an E3 or E4 finding, with rates of 14.7% (538/3659) and 11.9% (370/3110), respectively (p = 0.008).
Discussion
C-RADS represents an important structured reporting construct [4] . As with BI-RADS in mammography, it standardizes terminology and classification of examination output as well as management options for colorectal cancer screening by CTC. Ultimately, it allows valid comparisons among different institutions for both clinical and research purposes. There are few data detailing the usage of C-RADS in the clinical screening setting since it was proposed in 2005. Only recently have such programmatic measures been reported in smaller single-institution series [16] . This study represents the results of a 7-year clinical CTC screening experience where C-RADS was prospectively applied to over 7000 patients. If clinical use of CTC for colorectal cancer screening increases, we offer our data-including distribution of C-RADS colorectal and extracolonic scores, colonoscopy referral percentage, and polyp output and characteristics-for use as benchmark values to guide other clinical screening programs and assist with quality improvement.
Our study shows that in an average-risk healthy screening population, the majority of CTC examinations (> 85%) are negative using the 6-mm threshold for positivity. At our center, the positive fraction (C2-C4 findings) ultimately led to a reasonable colonoscopy referral rate of less than 10%, with the option of imaging surveillance for one or two isolated small polyps (C2 findings) available and the threshold for examination positivity set at 6 mm. The fraction of patients with C2 findings opting for CTC surveillance over immediate polypectomy may vary considerably among programs and will also be influenced by evolving data on the natural history of small polyps [17, 18] . Although about two thirds of our patients with one or two small polyps found at CTC screening (i.e., C-RADS C2) will initially opt for CTC surveillance, nearly one quarter will later switch to colonoscopy for polypectomy. In our experience, this follow-up decision is typically related to input from the patient's primary care provider, who are often not aware of all the relative risks and benefits involved with this decision [19, 20] . Regardless, this is a complex decision that can be influenced by many factors, including patient preference, understanding of relative risks, insurance coverage, demographic and risk factors, and whether the counseling is coming from radiology, gastroenterology, or primary care.
For practical purposes, C-RADS places screened patients with C1 findings with potential isolated diminutive polyps (≤ 5 mm) into a 5-year follow-up interval (i.e., routine screen interval for negative examinations) [21] . The selective polypectomy approach advanced by C-RADS achieves what we think is the primary target of colorectal screeningthat is, early detection of advanced neoplastic lesions-but also realizes a marked decrease in polypectomies and associated complications compared with universal polypectomy strategies observed in colonoscopic programs [5] . The difference in polypectomy rates between CTC and colonoscopy screening, which can be over fourfold in magnitude, is almost entirely due to the different handling of diminutive lesions from setting the positivity threshold at 6 mm for CTC. In our series, the majority of the CTC-detected polyps (nearly 98%) were classified with moderate or high diagnostic confidence. Programs that include radiologists with appropriate (CTCspecific) training should expect similar numbers. Using this systematic approach, we have shown that the variation in lesion detection rates among radiologists in our program is quite narrow [22] , especially compared with the wide variation in performance typically seen at colonoscopy [23] .
Our study shows that demographic considerations become important, particularly
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when referencing these data as programmatic benchmarks. The effects of age and sex are significant because both have also been shown to be strongly associated with colorectal neoplasia risk [24] . As expected, positive examinations in this study increased dramatically with age, with the rate seen in patients 65-79 years old approximately double that of patients 50-64 years old. Also as expected, the rate increased substantially among men compared with women. Thus, the cohort composition of these two factors should be taken into consideration as programs compare output with these values. Our reported results also reinforce likely explanations regarding the differences in positive and advanced neoplasia rates reported in the literature [18] . For example, Lieberman et al. [25] reported an advanced adenoma rate of 10.5% in an older male cohort of Veterans Administration patients, whereas such rates have been much lower in other screening series with younger female-dominated populations [5, 18, 26] .
Interestingly, although men had a significantly higher rate of C2 and C3 findings, there was no difference observed between the sexes with regard to C4 findings (defined as colorectal mass, likely malignant). At face value, this result appears somewhat surprising. Besides higher rates of adenomatous polyps, it is well established that men have higher overall rates of adenocarcinoma than women [27] . However, the lack of a sex difference in the C4 rates may be related to the imaging-based nature of the classification. Although most C4 lesions prove to be malignant, benign causes such as focal diverticular strictures are included in this group because there is currently no other way to categorize them. Taken together, the group of focal concentric masses of various causes led to similar rates between men and women in this study. Future iterations of the C-RADS construct should take these likely benign masses into consideration.
The nondiagnostic study rate was less than 1% for this screening cohort. This points to the robust reproducible nature of CTC and compares favorably against incomplete colonoscopy rates, which are reported to be as high as 13% [28] . Furthermore, there is generally much more diagnostic information contained within a C0 CTC examination compared with an incomplete optical colonoscopy, because the entire colon is always visualized to some degree in the former but is completely nonvisualized proximal to the point of scope passage in the latter. The nondiagnostic rate at CTC is another important quality metric against which other programs can measure. In our experience, approximately one third of nondiagnostic examinations were related to the bowel preparation, one half to distention, and the remainder to a combination of the two factors. If substantially higher rates are seen in other programs, this metric should prompt programmatic review for potentially correctable causes such as an insufficient bowel preparation or setting the threshold for distention adequacy too high. The C0 rate will also be influenced by the experience and comfort level of the interpreting radiologist when dealing with a suboptimal CTC examination.
The results of this study are particularly important with regard to extracolonic findings. The cross-sectional nature of CTC allows diagnoses outside of the colorectum [15, 29] . It is imperative to minimize unnecessary workup while maintaining the ability to uncover important diagnoses, such as extracolonic cancers and vascular aneurysms. The percentages seen here should help in establishing baseline values for the E categories of C-RADS to allow comparison with other screening programs with comparable demographics. Once set, programmatic and individual radiologist percentages can be compared for the identification of outliers. Such quality measures would be helpful to help optimize the evaluation of incidental findings. It is particularly important to prevent radiologist practices that artificially upstage E2 findings (benign findings that do not require additional workup) because of "defensive medicine" approaches. Going forward, E4 (potentially important) findings should be emphasized because most E3 (likely unimportant) findings will ultimately prove to be of little or no clinical relevance.
The E3 and E4 cohort represents the pool of incidental extracolonic findings that may generate additional imaging. For patients with E4 findings, additional workup of some sort is typically mandatory, whereas it may or may not be indicated in patients with E3 findings, depending on the specific clinical situation. By definition, no workup is recommended for an incidental E2 finding or for a negative E1 examination. In our study, this rate for potential additional evaluation was 13%. It is important to recognize that this represents the upper limit of possible workup. A previous analysis of a portion of this population (n = 2195) showed that the actual workup rate was only 6.1% [30] . This mirrors other such studies where the actual workup rate was substantially smaller than the overall E3 and E4 rate. Zalis et al. [28] reported an actual workup rate of 5.5% from the E3 and E4 cohort in a large prospective multicenter laxative-free CTC trial (n = 605). Possible explanations for this observation include redemonstration of previously known findings or intentional deferral of further investigation because of the specific situation of the patient.
Conducting this study has allowed us to identify several issues with C-RADS that may require revision in the future. On the colorectal side, modification to separate out likely submucosal, extrinsic, or nonneoplastic lesions would be helpful because they often do not fit neatly in the positive categories of C2-C4. Likely benign masslike lesions (e.g., diverticular strictures) have already been discussed. On the extracolonic side, the current integration of clinical significance and need for further workup creates difficulties in interpreting the E categories. Because of this combination, it is difficult to determine the true rate of recommended workup related to extracolonic findings because additional workup is not appropriate for all E3 findings even though they may still be considered significant. Separation of finding significance and management recommendation in the lexicon would be helpful.
We have identified limitations to this study. Our data were collected in the setting of a single academic center in the midwestern United States, and our screening patient population is relatively young and healthy with a higher percentage of women than many other colorectal cancer screening experiences. Therefore, there may be issues when generalizing our results to other locales and patient populations. There exists the possibility of selection bias in our sample because we are dependent on primary physician referral for our patient volume, but this is likely to be the case in many clinical screening programs. In addition, all radiologists at our institution use 3D reconstructions for primary polyp detection with 2D cross-sectional series for primary confirmation and secondary detection; consequently, our results may not generalize to centers where a combined approach is not used [11] .
In conclusion, we report the results of our 7-year experience with a clinical CTC screening program. The majority of examinations are negative for polyps at a 6-mm threshold with a reasonable referral rate to colonoscopy. Extracolonic findings potentially requiring additional evaluations constitute a low 
